Sasaki Y, Imaoka S, Masutani S, Iwamoto S, Kishimoto S, Nakamori S, Kameyama M, Ohigashi H, Hiratsuka M, Ishikawa O
Dept. of Surgery, Center for Adult Diseases, Osaka.
Gan To Kagaku Ryoho. 1993 Aug;20(11):1469-72.
In 304 patients with hepatocellular carcinoma who underwent hepatic resection, 162 patients received chemoembolization before surgery (group A) and the remaining 142 patients received no therapy before surgery (group B). The 5-year disease-free survival (DFS) of group A and B were 36% and 21%, respectively, and there were no significant differences between them. In the groups of patients with good liver function (Child A), or patients with solitary tumor, or patients with tumors more than 5 cm in size, DFSs of group A were significantly better than those of group B. The difference of DFS between group A and B was largest in the group of the patients with tumors more than 5 cm in size.
在304例行肝切除的肝细胞癌患者中，162例患者在手术前接受了化疗栓塞（A组），其余142例患者在手术前未接受任何治疗（B组）。A组和B组的5年无病生存率分别为36%和21%，两组之间无显著差异。在肝功能良好（Child A级）的患者组、单发肿瘤患者组或肿瘤大小超过5 cm的患者组中，A组的无病生存率显著高于B组。A组和B组之间的无病生存率差异在肿瘤大小超过5 cm的患者组中最大。
